Published in Biotech Business Week, October 15th, 2007
"We reduced the need to take nicotine by blocking CRF-1 receptors in the brain," says Olivier George, a research associate in the Scripps Research Koob lab who conducted the study with Sandy Ghozland and other colleagues. "We were surprised by the compound's dramatic...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.